<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001844550</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001817713</issuerCik>
      <issuerName>Janux Therapeutics, Inc.</issuerName>
      <secFileNumber>001-40475</secFileNumber>
      <issuerAddress>
        <com:street1>10955 VISTA SORRENTO PARKWAY</com:street1>
        <com:street2>SUITE 200</com:street2>
        <com:city>SAN DIEGO</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>92130</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>(858) 751-4493</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Avalon BioVentures SPV I, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>10% Stockholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Wells Fargo Clearing Services</name>
        <address>
          <com:street1>1 North Jefferson Avenue</com:street1>
          <com:city>St. Louis</com:city>
          <com:stateOrCountry>MO</com:stateOrCountry>
          <com:zipCode>63103</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>92200</noOfUnitsSold>
      <aggregateMarketValue>4350513.35</aggregateMarketValue>
      <noOfUnitsOutstanding>52164498</noOfUnitsOutstanding>
      <approxSaleDate>09/26/2024</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>common</securitiesClassTitle>
      <acquiredDate>03/01/2021</acquiredDate>
      <natureOfAcquisitionTransaction>Conversion</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>92200</amountOfSecuritiesAcquired>
      <paymentDate>03/01/2021</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Avalon Bioventures SPV I L.P.</name>
        <address>
          <com:street1>10955 Vista Sorrento Parkway</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92130</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Janux Therapeutics, Inc.</securitiesClassTitle>
      <saleDate>09/12/2024</saleDate>
      <amountOfSecuritiesSold>161356</amountOfSecuritiesSold>
      <grossProceeds>7583732.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Avalon Bioventures SPV I L.P.</name>
        <address>
          <com:street1>10955 Vista Sorrento Parkway</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92130</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Janux Therapeutics, Inc.</securitiesClassTitle>
      <saleDate>09/10/2024</saleDate>
      <amountOfSecuritiesSold>46604</amountOfSecuritiesSold>
      <grossProceeds>2168465.48</grossProceeds>
    </securitiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Avalon Bioventures SPV I L.P.</name>
        <address>
          <com:street1>10955 Vista Sorrento Parkway</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92130</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Janux Therapeutics, Inc.</securitiesClassTitle>
      <saleDate>09/06/2024</saleDate>
      <amountOfSecuritiesSold>110644</amountOfSecuritiesSold>
      <grossProceeds>4647048.00</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>Tighe Reardon is a General Partner for Avalon Bioventures SPV I L.P.</remarks>
    <noticeSignature>
      <noticeDate>09/26/2024</noticeDate>
      <signature>Tighe Reardon</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4908}]
144
0001844550
XXXXXXXX
LIVE
0001817713
Janux Therapeutics, Inc.
001-40475
10955 VISTA SORRENTO PARKWAY
SUITE 200
SAN DIEGO
CA
92130
(858) 751-4493
Avalon BioVentures SPV I, L.P.
10% Stockholder
common
Wells Fargo Clearing Services
1 North Jefferson Avenue
St. Louis
MO
63103
92200
4350513.35
52164498
09/26/2024
Nasdaq
common
03/01/2021
Conversion
Issuer
N
92200
03/01/2021
N/A
N
Avalon Bioventures SPV I L.P.
10955 Vista Sorrento Parkway
Suite 200
San Diego
CA
92130
Janux Therapeutics, Inc.
09/12/2024
161356
7583732.00
Avalon Bioventures SPV I L.P.
10955 Vista Sorrento Parkway
Suite 200
San Diego
CA
92130
Janux Therapeutics, Inc.
09/10/2024
46604
2168465.48
Avalon Bioventures SPV I L.P.
10955 Vista Sorrento Parkway
Suite 200
San Diego
CA
92130
Janux Therapeutics, Inc.
09/06/2024
110644
4647048.00
Tighe Reardon is a General Partner for Avalon Bioventures SPV I L.P.
09/26/2024
Tighe Reardon